Evidence map›Paper›PMID 41810918›Full record

ArticleAnalytical cellular pathology (Amsterdam)2026

CCDC97 is a Promising Predictor in Cancer Diagnosis: A Pan Cancer Analysis.

Changye Yang, Ruirui Yang, Rundong Wang, Guo Ma, Lixin Hua

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytical cellular pathology (Amsterdam), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Changye YangDepartment of Clinical Medicine, Affiliated Huishan Hospital of Xinglin College, Nantong University, No.2 Zhanqian North Road, Wuxi, 214000, Jiangsu, China, ntu.edu.cn.
Ruirui YangMinistry of Science and Education, Affiliated Huishan Hospital of Xinglin College, Nantong University, No.2 Zhanqian North Road, Wuxi, 214000, Jiangsu, China, ntu.edu.cn.
Rundong WangSchool of Clinical and Basic Medicine, Shandong First Medical University, Jinan, China, sdfmu.edu.cn.
Guo MaSchool of Pharmacy, National Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai, China, fudan.edu.cn.
Lixin HuaDepartment of General Surgery, Affiliated Huishan Hospital of Xinglin College, Wuxi Huishan District People's Hospital, Nantong University, Wuxi, China, ntu.edu.cn.ORCID https://orcid.org/0000-0003-0416-9930

Funding

Nantong University 2024JZ044Natural Science Foundation of Shandong Province ZR2020MC073University Student Innovation and Entrepreneurship Program S202010439049
6 · The paper itself

Abstract

backgroundCoiled-coil domain-containing 97 (CCDC97) can bind to the splicing factor SF3B complex to participate significantly in pre-mRNA splicing. However, there may be a risk of cancer development in the case of disrupted mechanism, necessitating further in-depth investigation of the underlying mechanism.

methodsThe present study was conducted by searching for various databases to implement a comprehensive cancer analysis of CCDC97. Furthermore, a competitive endogenous RNA (ceRNA) network of CCDC97 was established, which was further integrated with the reported oncogene mechanisms in the CCDC family to explain the potential reasons for its abnormal expression.

resultsCCDC97 is highly expressed in various cancers and closely associated with poor prognosis. CCDC97 was also strongly associated with the infiltration of various immune cells and multiple immune checkpoints in the tumor immune microenvironment. RT-qPCR showed that CCDC97 was highly expressed in hepatocellular carcinoma (HCC) tissue samples. At the single-cell level, CCDC97 exhibited an intimate association with depleted T cells in HCC tissues.

conclusionIn cancers, particularly in HCC CCDC97 can serve as a promising marker for immunotherapy and prognosis in cancers, particularly in HCC. More experimental verification is needed in the future research.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularLiver NeoplasmsNeoplasmsGene Expression Regulation, NeoplasticHumansPrognosisRNA, Competitive EndogenousTumor MicroenvironmentBiomarkers, TumorRNA, Competitive EndogenousCCDC97ceRNA networkDNA methylationimmune cell infiltrationpan cancer

Identifiers

PMID41810918
PMCPMC13580819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.